As insulin becomes an increasingly common treatment for patients with type 2 diabetes, [5] these findings highlight the critical need for studies of the comparative effects of continuing versus stopping insulin secretagogues and newer diabetes medications after insulin is started. The gene discussed is INS; the disease is diabetes mellitus.